![](https://www.lachmanconsultants.com/wp-content/uploads/2021/06/iStock-1063277566.jpg)
Benzodiazepines in the Crosshairs?
In previous blogs (here, here, here, and here), we discussed abuse-deterrent formulations and the potential “creep” in applying this approach towards substances other than opioids. So far, we have not seen a big move in that direction, most likely because of the lack of any great success of currently approved abuse-deterrent formulations from actually preventing […]